Novo Nordisk stock dips as DKK 15 billion buyback advances
Published on 09/09/2026 at 15:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk A/S stock (ISIN DK0060534915) is trading well below its recent highs, with the US-listed NVO shares around USD 45 as of early September 2026, while the Danish group continues a substantial DKK 15 billion share buyback programme that has already retired more than 32 million B shares.
Share buyback programme supports capital return
According to Novo Nordisk on September 7, 2026, the company has been executing a share repurchase programme under EU safe harbour rules that forms part of a broader plan to buy back up to DKK 15 billion of B shares over the 12-month period beginning February 4, 2026.
Between September 1 and September 4, 2026, Novo Nordisk bought back 845,000 B shares at average daily prices between DKK 293.94 and DKK 305.35, corresponding to a transaction value of about DKK 252.8 million over those four trading days.Novo Nordisk The update shows that, under the current programme initiated May 6, 2026, the company has repurchased 17,275,000 B shares for a cumulative value of DKK 5.22 billion.
As of September 4, 2026, Novo Nordisk reports that it has bought back a total of 32,034,179 B shares since February 4, 2026 at an average price of DKK 281.63, corresponding to an aggregate transaction value of DKK 9.02 billion, and now holds 46,074,876 B shares as treasury stock, equal to about 1.0 percent of its share capital.StockTitan For investors, this level of buyback activity is a clear capital-return signal that can underpin earnings per share over time.
Analyst valuation signals and recent price move
The recent price action has been negative despite the buyback. On September 8, 2026, Novo Nordisk NVO shares fell about 3.1 percent to USD 45.16, marking a notable single-day decline from the prior close of USD 46.63.GuruFocus Intraday data from Nasdaq-linked portals on September 9, 2026 show the stock trading around USD 45.36, down roughly 2.7 percent on the day, with a 52-week range between USD 35.12 and USD 64.16.CNBC
Market cap figures from stock portals point to a Novo Nordisk equity value of around USD 200.8 billion as of early September 2026, based on a share price in the mid-USD 40s and daily trading volume of about 2.2 million NVO shares.Kraken That places the current US price clearly closer to the lower end of the 52-week trading range than to the high, a point many valuation-focused investors may note.
Despite the share price weakness, valuation models from some research platforms classify the stock as significantly undervalued. According to GuruFocus on September 8, 2026, the GF Value framework estimates an intrinsic value of USD 108.37 per share for Novo Nordisk, implying that the then-current price of USD 45.16 was about 58.3 percent below that estimate. The same analysis notes that the trailing P/E ratio of roughly 11.4 is far below a five-year median P/E around 35.4, which, in their view, strengthens the case that Novo Nordisk stock may be trading at a discount to its longer-term valuation benchmarks.
Fundamental outlook and guidance context
While the latest full quarterly report is not within the week-filtered search set, current analyst consensus estimates provide a snapshot of expectations for Novo Nordisk’s near-term fundamentals. According to Yahoo Finance, analysts covering Novo Nordisk expect revenue of about DKK 72.84 billion for the current quarter ending September 2026 and DKK 73.87 billion for the next quarter ending December 2026. For the full fiscal year 2026, the average revenue estimate stands around DKK 299.38 billion, rising slightly to DKK 303.93 billion in 2027.
On the earnings side, the same consensus table shows an average EPS forecast of 5.11 (currency in DKK terms) for the current quarter, 4.37 for the next quarter, and 23.03 for the full year 2026, with 21.98 expected for 2027.Yahoo Finance The spread between low and high estimates indicates that analysts are broadly aligned on solid double-digit revenue and earnings levels, even if the stock price currently reflects concerns about competition, regulatory risk or demand normalization in obesity and diabetes therapies.
Dividend and payout metrics also play into the fundamental picture. Recent valuation commentary notes a dividend yield near 3.9 percent for Novo Nordisk, combined with a payout ratio that is considered sustainable when set against earnings and cash generation.GuruFocus Together with the ongoing buyback, that suggests a combined shareholder-return strategy where cash dividends and share repurchases both contribute to total yield.
Capital Markets Day and strategic narrative
Novo Nordisk also maintains a detailed investor-relations presence and hosts events to explain its long-term strategy. The company has scheduled a Capital Markets Day 2026, with webcasts and materials accessible via its investors portal.Novo Nordisk Such events typically focus on the growth trajectory of key products like obesity drug Wegovy and diabetes treatments, pipeline progress and margin sustainability.
Recent commentary highlights that management continues to advocate for regulated, prescription-based use of weight-loss medicines and warns about risks from unregulated peptide markets.GuruFocus For investors, the regulatory environment and competitive dynamics in obesity and cardiometabolic drugs are key medium-term risks alongside the opportunity, and the combination of a large buyback and detailed strategic messaging can be read as a sign of confidence in the underlying business.
Stock near lower end of its 52-week range
In US trading, Novo Nordisk stock recently changed hands around USD 45.36 on Nasdaq on September 9, 2026, with an intraday range between roughly USD 45.31 and USD 45.91 and a prior closing level at USD 46.63, implying a daily decline of about 2.7 percent at that snapshot.CNBC With the current price sitting closer to the 52-week low of USD 35.12 than to the high of USD 64.16, the market is valuing Novo Nordisk stock at a discount to the peak levels seen over the past year even as buybacks and dividend payments continue.
Novo Nordisk stock at a glance
- Company: Novo Nordisk A/S
- ISIN: DK0060534915
- Ticker: NVO
- Trading venue: Nasdaq (US listing)
- Price (as of September 9, 2026): 45.36 USD
- Market capitalization: 200.84 billion USD (as of September 9, 2026)
- Sector / Industry: Health care / Pharmaceuticals
- Index membership: S&P 500
